Grifols Sa Revenue Growth Rates (GRFS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Grifols Sa  (NASDAQ: GRFS)
 

GRFS's Revenue Growth by Quarter and Year

Grifols Sa's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GRFS Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 8,426.88
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 8,426.88





GRFS Revenue fourth quarter 2025 Y/Y Growth Comment
Grifols Sa showed record Revenue improvement in the fourth quarter 2025 with 4.32% from the fourth quarter 2025 2024, to $ 8,426.88 millions.
This represents worst decline in recent Company history.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 129 other companies have achieved higher Revenue growth. While Grifols Sa' s Revenue increase of 4.32% ranks overall at the positon no. 2232 in the fourth quarter 2025.


GRFS Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 4.32 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   4.32 % - - -

Financial Statements
Grifols Sa's fourth quarter 2025 Revenue $ 8,426.88 millions GRFS's Income Statement
Grifols Sa's fourth quarter 2024 Revenue $ 8,077.87 millions Quarterly GRFS's Income Statement


GRFS Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   4.32 % - - -


Back to GRFS Growth rate Comparisons >> Back to GRFS Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #345
Overall #2232

Revenue Y/Y Growth Statistics
High Average Low
4.32 % 4.32 % 4.32 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #345
Overall #2232
Revenue Y/Y Growth Statistics
High Average Low
4.32 % 4.32 % 4.32 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Grifols Sa's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GRFS's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GRFS's IV. Quarter Q/Q Revenue Comment


Grifols Sa's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 8,426.88 $ 8,077.87 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 4.32 % - - - -
Year on Year Revenue Growth Overall Ranking # 2099 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 4.32 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 2205 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 4.32% annual Revenue growth, Grifols Sa would report a record annual Revenue improvement if the fiscal year would end on Dec 31 2025.

In the Healthcare sector 315 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2099.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 114
Healthcare Sector # 316
Overall # 2099

Revenue TTM Y/Y Growth Statistics
High Average Low
4.32 %
 4.32 %
4.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 114
Sector # 330
S&P 500 # 2205
Cumulative Revenue growth Comment
With 4.32% annual Revenue growth, Grifols Sa would report a record annual Revenue improvement if the fiscal year would end on Dec 31 2025.

In the Healthcare sector 315 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2099.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 114
Healthcare Sector # 316
Overall # 2099

Revenue TTM Y/Y Growth Statistics
High Average Low
4.32 %
4.32 %
4.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 114
Sector # 330
S&P 500 # 2205




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GRFS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Stevanato Group S p a 7.45%$ 7.450 millions
United Therapeutics Corporation7.38%$ 7.379 millions
Fulgent Genetics Inc 7.36%$ 7.364 millions
Icon Plc7.29%$ 7.287 millions
Adm Tronics Unlimited Inc 7.15%$ 7.148 millions
Quest Diagnostics Inc7.06%$ 7.058 millions
Infusystem Holdings Inc7.04%$ 7.037 millions
Pluri Inc 7.03%$ 7.027 millions
Sinovac Biotech Ltd7.01%$ 7.013 millions
Ge Healthcare Technologies Inc 6.87%$ 6.865 millions
Waters Corporation6.83%$ 6.835 millions
Progyny Inc 6.83%$ 6.829 millions
Alpha Pro Tech Ltd 6.73%$ 6.730 millions
Hca Healthcare Inc 6.72%$ 6.716 millions
Uniqure N v 6.65%$ 6.646 millions
Healthcare Services Group Inc 6.59%$ 6.594 millions
Sonida Senior Living Inc 6.23%$ 6.226 millions
Dentsply Sirona Inc 6.19%$ 6.188 millions
Acadia Healthcare Company Inc 6.10%$ 6.099 millions
Smith and Nephew Plc6.09%$ 6.093 millions
Qiagen N v 6.00%$ 5.999 millions
Cytek Biosciences Inc 5.95%$ 5.949 millions
Revvity Inc5.85%$ 5.852 millions
Sanara Medtech Inc 5.66%$ 5.662 millions
Labcorp Holdings Inc 5.60%$ 5.599 millions
Sanofi5.49%$ 5.487 millions
Align Technology inc 5.19%$ 5.186 millions
Pacira Biosciences inc 5.14%$ 5.137 millions
Illumina Inc 4.98%$ 4.982 millions
Viatris Inc 4.97%$ 4.974 millions


About Grifols Sa Revenue Growth Rates (GRFS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Grifols Sa (CIK 1438569).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-044901
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Grifols Sa’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.